# Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

> **NCT03696784** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Lymphoma
- Lymphoma, B-Cell
- Immune System Diseases
- Immunoproliferative Disorders
- Lymphatic Diseases

## Interventions

- **BIOLOGICAL:** iC9-CAR19 T cells
- **DRUG:** Bendamustine
- **DRUG:** Fludarabine
- **DRUG:** AP1903
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03696784
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-12
- **Primary completion:** 2025-08-31
- **Final completion:** 2040-07-31
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03696784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03696784, "Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03696784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*